MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Quantitative assessment of advanced therapies in Parkinson’s disease using the Parkinson kinetigraph (PKG)

R.L. Blaze, J. Tan, A.H. Evans (Parkville, Australia)

Meeting: 2016 International Congress

Abstract Number: 578

Keywords: Apomorphine, Deep brain stimulation (DBS), Levodopa(L-dopa)

Session Information

Date: Tuesday, June 21, 2016

Session Title: Technology

Session Time: 12:30pm-2:00pm

Location: Exhibit Hall located in Hall B, Level 2

Objective: Our aim was to establish whether objective measurements using the Parkinson’s Kinetigraph can detect differences between patients undergoing different advanced therapy with either deep brain stimulation (DBS) or continuous infusion therapy (CIT).

Background: Continuous infusion therapy (with either levodopa-carbidopa intestinal gel or apomorphine) and DBS constitute our current armamentarium of advanced therapies in the management of Parkinson’s disease. Clinical algorithms for choice of advanced therapy are currently lacking and there are no currently widely accepted objective tools to aid decision-making. The PKG is a wrist-worn accelerometer that has been demonstrated to provide reliable quantitative measures of bradykinesia, dyskinesia and motor fluctuation. Using the PKG to objectively assess indications for advanced therapies and outcomes following initiation of these treatments may lead to better selection therapies for individual patients.

Methods: The PKG was worn by patients with Parkinson’s disease for a minimum of 6 days before and after the initiation of treatment with an advanced therapy. Eleven patients were treated with DBS and 10 patients were treated with CIT (5 with apomorphine and 5 with levodopa-carbidopa intestinal gel). Motor performance was assessed using the PKG measures of bradykinesia (BK), dyskinesia (DK) and motor fluctuation (FDS).

Results: Mean age at baseline was comparable for DBS and CIT patients but prior to treatment, DBS patients had lower BK scores and higher FDS scores compared to the CIT group. Within the DBS group, significantly higher BK scores and lower FDS scores were recorded post treatment. Within the CIT group there were no significant differences in BK, DK or FDS scores following treatment. Post treatment differences in scores between groups were not found although the sample size is small.

Baseline PKG measurements for patients according to treatment group
Treatment group Mean age (years) Mean BK Mean DK Mean FDS
DBS 67.7 18.9 12.9 12.7
CIT 66.3 25.1 4.0 8.5
DBS = deep brain stimulation, CIT = continuous infusion therapy, BK = bradykinesia score, DK = dyskinesia score, FDS = motor fluctuation score“

Conclusions: The findings suggest that infusion therapies are often selected in patients with a more advanced state of disease at the time of initiation. They also suggest that the PKG may be a useful tool to aid the selection of advanced therapy for patients with Parkinson’s disease. Furthermore, predicted patterns of change following initiation of an advanced therapy may be assessed quantitatively using the PKG which will help with titration of treatment, assessment of clinical outcome and provide a useful tool for further research.

To cite this abstract in AMA style:

R.L. Blaze, J. Tan, A.H. Evans. Quantitative assessment of advanced therapies in Parkinson’s disease using the Parkinson kinetigraph (PKG) [abstract]. Mov Disord. 2016; 31 (suppl 2). https://www.mdsabstracts.org/abstract/quantitative-assessment-of-advanced-therapies-in-parkinsons-disease-using-the-parkinson-kinetigraph-pkg/. Accessed May 15, 2025.
  • Tweet
  • Email
  • Print

« Back to 2016 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/quantitative-assessment-of-advanced-therapies-in-parkinsons-disease-using-the-parkinson-kinetigraph-pkg/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Yerba Mate (Ilex paraguaiensis) protects dopaminergic neurons degeneration and improve their maturation in culture
  • #26133 (not found)
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley